Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 15/20 | 0.48 |
| ▸ | MMP1 | P03956 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP8 | P22894 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973555 | 0.97 | CA2 (0.48) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4937413 | 0.97 | CA2 (0.54) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29831834 | 0.97 | CA2 (0.54) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5188600 | 0.97 | CA2 (0.54) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29263304 | 0.97 | CA2 (0.54) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL31520150 | 0.97 | CA2 (0.54) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL828147 | 0.97 | CA2 (0.54) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL31370416 | 0.95 | CA2 (0.52) | CA2F2PRSS1PRSS2PRSS3 | |
| Bromide SCHEMBL29742768 | 0.95 | CA2 (0.52) | CA2F2PRSS1PRSS2PRSS3 | |
| Ammonia Solution, Strong SCHEMBL31424949 | 0.95 | CA2 (0.52) | CA2F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015255-A1 | Pharmaceutical Compositions Based on Fluorinated Sulphamides and Sulphinimides | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(C.N.R.S.) (FR) | 2008-01-17 | — | — | US | disclosed |
| US-6461805-B1 | CONTAINING ORGANOSILICON COMPOUND | KONICA CORPORATION | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015255-A1 | Pharmaceutical Compositions Based on Fluorinated Sulphamides and Sulphinimides | FPR3, FPR1, AFF1 | CA2 893/4885F2 167/4885PRSS1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.